HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.

AbstractOBJECTIVE:
Although the route of estrogen administration is known to be an important determinant of the thrombotic risk among postmenopausal women using hormone therapy, recent data have shown that norpregnane derivatives but not micronized progesterone increase venous thromboembolism risk among transdermal estrogens users. However, the differential effects of progesterone and norpregnanes on hemostasis have not yet been investigated.
METHODS:
We set up a cross-sectional study among healthy postmenopausal women aged 45 to 70 years. The impact of activated protein C (APC) on endogenous thrombin potential was investigated in the plasma samples of 108 women who did not use any hormone therapy (n = 40) or who were treated with transdermal estrogens combined with micronized progesterone (n = 30) or norpregnane derivatives (n = 38).
RESULTS:
After exclusion of women with factor V Leiden and/or G20210A prothrombin gene mutations, there was no significant change in APC sensitivity among women who used transdermal estrogens combined with micronized progesterone compared with nonusers. Women using transdermal estrogens combined with norpregnanes were less sensitive to APC than were nonusers (P = 0.003) or users of transdermal estrogens combined with micronized progesterone (P = 0.004). In addition, prothrombin fragment 1 + 2 concentration was higher in users of transdermal estrogens plus norpregnanes than in nonusers (P = 0.004). Other hemostatic parameters did not vary significantly across the different subgroups.
CONCLUSIONS:
Transdermal estrogens combined with norpregnanes may induce APC resistance and activate blood coagulation. These results provide a biological support to epidemiological data regarding the potential thrombogenic effects of norpregnanes. However, these findings need to be confirmed in a randomized trial.
AuthorsMarianne Canonico, Martine Alhenc-Gelas, Geneviève Plu-Bureau, Valérie Olié, Pierre-Yves Scarabin
JournalMenopause (New York, N.Y.) (Menopause) 2010 Nov-Dec Vol. 17 Issue 6 Pg. 1122-7 ISSN: 1530-0374 [Electronic] United States
PMID20613675 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Estrogens
  • Norpregnanes
  • Peptide Fragments
  • Progestins
  • prothrombin fragment 1.2
  • Prothrombin
  • Thrombin
Topics
  • Activated Protein C Resistance (blood, etiology)
  • Administration, Cutaneous
  • Aged
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Estrogen Replacement Therapy (adverse effects)
  • Estrogens (administration & dosage, adverse effects)
  • Female
  • Hemostasis (drug effects)
  • Humans
  • Linear Models
  • Middle Aged
  • Norpregnanes (administration & dosage, adverse effects)
  • Peptide Fragments (blood, drug effects)
  • Postmenopause (blood)
  • Progestins (administration & dosage, adverse effects)
  • Prothrombin (drug effects)
  • Thrombin (biosynthesis, drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: